SV2011003915A - Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia - Google Patents
Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopeniaInfo
- Publication number
- SV2011003915A SV2011003915A SV2011003915A SV2011003915A SV2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A SV 2011003915 A SV2011003915 A SV 2011003915A
- Authority
- SV
- El Salvador
- Prior art keywords
- trombocitopenia
- thrombocitopenia
- reducing
- mortality associated
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE DESCRIBEN MÉTODOS PARA REDUCIR EL RIESGO DE MORTALIDAD Y MORBILIDAD ASOCIADAS A TROMBOCITOPENIA Y PARA REDUCIR EL RIESGO DE TROMBOCITOPENIA EN PACIENTES CUYO TRATAMIENTO REQUIERE INHIBICIÓN DE LA AGREGACIÓN PLAQUETARIA. LOS MÉTODOS INVOLUCRAN LA ADMINISTRACIÓN DE UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE TIROFIBÁN
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11697608P | 2008-11-21 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2011003915A true SV2011003915A (es) | 2011-07-01 |
Family
ID=42198725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2011003915A SV2011003915A (es) | 2008-11-21 | 2011-05-23 | Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120059036A1 (es) |
EP (1) | EP2355824A4 (es) |
KR (1) | KR20110108330A (es) |
AU (1) | AU2009318101A1 (es) |
BR (1) | BRPI0920984A2 (es) |
CL (1) | CL2011001175A1 (es) |
CO (1) | CO6390039A2 (es) |
CR (1) | CR20110271A (es) |
DO (1) | DOP2011000149A (es) |
EC (1) | ECSP11011152A (es) |
MA (1) | MA32820B1 (es) |
MX (1) | MX2011005376A (es) |
NI (1) | NI201100101A (es) |
PE (1) | PE20110946A1 (es) |
SV (1) | SV2011003915A (es) |
TN (1) | TN2011000256A1 (es) |
WO (1) | WO2010059244A2 (es) |
ZA (1) | ZA201103741B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101996880B1 (ko) | 2018-03-16 | 2019-07-05 | 경성대학교 산학협력단 | 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물 |
CN112441962A (zh) * | 2019-09-04 | 2021-03-05 | 武汉武药科技有限公司 | 替罗非班及其纯化方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
HUP0303917A2 (hu) * | 2001-01-26 | 2004-03-01 | Schering Corporation | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére |
US6770660B2 (en) | 2002-05-06 | 2004-08-03 | Artery Llc | Method for inhibiting platelet aggregation |
KR20050057294A (ko) * | 2002-09-09 | 2005-06-16 | 트라이젠 리미티드 | 보론산 염, 및 혈전증의 치료를 위한 그것의 용도 |
KR20070032648A (ko) * | 2004-05-12 | 2007-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전 상태의 치료에 유용한 p2y1 수용체의 우레아길항제 |
AU2005296305A1 (en) * | 2004-10-12 | 2006-04-27 | Decode Genetics Ehf | Sulfonamide peri-substituted bicyclics for occlusive artery disease |
-
2009
- 2009-11-20 KR KR1020117011598A patent/KR20110108330A/ko not_active Application Discontinuation
- 2009-11-20 PE PE2011001062A patent/PE20110946A1/es not_active Application Discontinuation
- 2009-11-20 MX MX2011005376A patent/MX2011005376A/es not_active Application Discontinuation
- 2009-11-20 WO PCT/US2009/006240 patent/WO2010059244A2/en active Application Filing
- 2009-11-20 AU AU2009318101A patent/AU2009318101A1/en not_active Abandoned
- 2009-11-20 US US13/130,340 patent/US20120059036A1/en not_active Abandoned
- 2009-11-20 EP EP09827893A patent/EP2355824A4/en not_active Withdrawn
- 2009-11-20 BR BRPI0920984A patent/BRPI0920984A2/pt not_active IP Right Cessation
-
2011
- 2011-05-19 CL CL2011001175A patent/CL2011001175A1/es unknown
- 2011-05-20 NI NI201100101A patent/NI201100101A/es unknown
- 2011-05-20 TN TN2011000256A patent/TN2011000256A1/fr unknown
- 2011-05-20 ZA ZA2011/03741A patent/ZA201103741B/en unknown
- 2011-05-20 DO DO2011000149A patent/DOP2011000149A/es unknown
- 2011-05-20 MA MA33876A patent/MA32820B1/fr unknown
- 2011-05-23 CR CR20110271A patent/CR20110271A/es not_active Application Discontinuation
- 2011-05-23 SV SV2011003915A patent/SV2011003915A/es unknown
- 2011-06-14 CO CO11073669A patent/CO6390039A2/es not_active Application Discontinuation
- 2011-06-20 EC EC2011011152A patent/ECSP11011152A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010059244A3 (en) | 2010-10-14 |
ZA201103741B (en) | 2012-01-25 |
US20120059036A1 (en) | 2012-03-08 |
EP2355824A4 (en) | 2012-11-07 |
NI201100101A (es) | 2011-12-19 |
PE20110946A1 (es) | 2012-01-05 |
CL2011001175A1 (es) | 2011-11-11 |
TN2011000256A1 (en) | 2012-12-17 |
BRPI0920984A2 (pt) | 2017-07-11 |
AU2009318101A1 (en) | 2010-05-27 |
KR20110108330A (ko) | 2011-10-05 |
EP2355824A2 (en) | 2011-08-17 |
MX2011005376A (es) | 2011-10-19 |
DOP2011000149A (es) | 2011-10-31 |
CR20110271A (es) | 2011-10-13 |
MA32820B1 (fr) | 2011-11-01 |
CO6390039A2 (es) | 2012-02-29 |
WO2010059244A2 (en) | 2010-05-27 |
ECSP11011152A (es) | 2011-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
GT201300234A (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida | |
CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
CR11749A (es) | Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina | |
EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
CL2013000735A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. | |
CO2018002534A2 (es) | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos | |
AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
EA201690327A1 (ru) | Терапевтические способы | |
AR085998A1 (es) | Aclidinio y su uso en la mejora de la calidad del sueño | |
UY31903A (es) | 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
SV2011003915A (es) | Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia | |
UY32507A (es) | Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo | |
AR076520A1 (es) | Parasiticidas sanguineos. composicion | |
AR094224A1 (es) | Composicion farmaceutica en forma de una suspension oral | |
CL2008002465A1 (es) | Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado. | |
AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
NI201200196A (es) | Agentes terapéuticos 976 | |
AR084169A1 (es) | Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab | |
DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek |